FDA and EMA accept Marstacimab regulatory submissions for the treatment of Hemophilia A and B

Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting

Merck and Moderna initiate Phase 3 study evaluating V940 (mRNA-4157) in combination with Keytruda for treatment of non-small cell lung cancer

The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)

Dr. Reddy's inks pact with Coya Therapeutics for development of sclerosis drug

Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya

Dupixent significantly reduced COPD exacerbations in second positive Phase 3 trial

Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease

Evive Biotech and Acrotech Biopharma receive FDA approval of Ryzneuta

BioPhy launches AI platform to accelerate the drug development market

The company has raised US$4.5 million in funding for its AI operating system

Bayer and Recursion focus research collaboration on Oncology

Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients

Can-Fite signs agreement with Collaborations Pharmaceuticals to develop anti-cancer drugs using AI

This project will aim to develop a next-generation A3 adenosine receptor drug agonists

Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru

Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution

Evonik strengthens nanoparticle technologies and services portfolio for parenteral drug delivery

Three block copolymers added to RESOMER portfolio of bioabsorbable polymers